Brielle Benyon

Brielle Benyon

Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.

Follow Brielle on Twitter @Brielle_Benyon.

Articles by Brielle Benyon

For many cancer survivors, the thought of returning to their cancer clinic after treatment ends may be off-putting, as it could bring up difficult memories. But Arleen Weitz could not wait to get back into the infusion center at the Sidney Kimmel Cancer Center (SKCC), Jefferson Health to do some good.

Prostate cancer is one of the most common cancers in males, with about one man in nine to be diagnosed during his lifetime, according to the American Cancer Society.

The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.